Estrogen plus progestin and risk of benign proliferative breast disease

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 9, 2008, Pages 2337-2343

  Rohan, Thomas E ^a   Negassa, Abdissa ^a   Chlebowski, Rowan T ^b   Lasser, Norman L ^c   McTiernan, Anne ^d   Schenken, Robert S ^e   Ginsberg, Mindy ^a   Wassertheil Smoller, Sylvia ^a   Page, David L ^f  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST DISEASE; BREAST EXAMINATION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; BIOPSY; BREAST DISEASES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; HYPERPLASIA; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED; POSTMENOPAUSE; PRECANCEROUS CONDITIONS; PROGESTINS; PROPORTIONAL HAZARDS MODELS; RISK; UNITED STATES;

EID: 53349117967     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0380     Document Type: Article

References (31)

1. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229-37.
2. Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005;353:275-85.
3. Wang DY, Fentiman I. Epidemiology and endocrinology of benign breast disease. Breast Cancer Res Treat 1985;6:5-36.
4. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999;187:272-8.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
6. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
7. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
8. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006;102:89-96.
9. Conner P. Breast response to menopausal hormone therapy-aspects on proliferation, apoptosis and mammographic density. Ann Med 2007;39:28-41.
10. Page DL, Schuyler PA, Dupont WD, et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 2003;361:125-9.
11. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 1992;23:1095-7.
12. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187-220.
13. Hays J, Hunt JR, Hubbell FA, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003;13:S18-77.
14. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-5.
15. Rohan TE, Miller AB. Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. Eur J Cancer Prev 1999;8:123-30.
16. Berkowitz GS, Kelsey JL, LiVolsi VA, et al. Exogenous hormone use and fibrocystic breast disease by histopathologic component. Int J Cancer 1984;34:443-9.
17. Friedenreich C, Bryant H, Alexander F, et al. Risk factors for benign proliferative breast disease. Int J Epidemiol 2000;29:637-44.
18. Rohan TE, Negassa A, Chlebowski RT, et al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized, controlled trial. J Natl Cancer Inst 2008;100:563-71.
19. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
20. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:1133-44.
21. Boyd NF, Lockwood GA, Martin LJ, et al. Mammographic density as a marker of susceptibility to breast cancer: a hypothesis. IARC Sci Publ 2001;154:163-9.
22. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356:227-36.
23. Boyd NF, Jensen HM, Cooke G, Han HL. Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst 1992;84:1170-9.
24. Boyd NF, Greenberg C, Lockwood G, et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. J Natl Cancer Inst 1997;89:488-96.
25. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-9.
26. McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: women's health initiative randomized trial. J Natl Cancer Inst 2005;97:1366-76.
27. Haslam SZ, Osuch JR, Raafat AM, Hofseth LJ. Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model. J Mammary Gland Biol Neoplasia 2002;7:93-105.
28. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 2005;96:95-108.
29. Ursin G, Hovanessian-Larsen L, Parisky YR, Pike MC, Wu AH. Greatly increased occurrence of breast cancers in areas of mammographically dense tissue. Breast Cancer Res 2005;7:R605-8.
30. Chlebowski R, Anderson G, Pettinger M, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 2008;168:370-7.
31. Rothman KJ. Modern Epidemiology. Boston: Little, Brown & Company; 1986. p. 106.